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Abstract: Smoking should be stopped and hypertension, diabetes mellitus, dyslipidemia, and 
hypothyroidism treated in elderly patients with peripheral arterial disease (PAD) of the lower 
extremities. Statins reduce the incidence of intermittent claudication and improve exercise dura-
tion until the onset of intermittent claudication in patients with PAD and hypercholesterolemia. 
Antiplatelet drugs such as aspirin or clopidogrel, especially clopidogrel, angiotensin-converting 
enzyme inhibitors, and statins should be given to all elderly patients with PAD without 
contraindications to these drugs. Beta blockers should be given if coronary artery disease is 
present. Exercise rehabilitation programs and cilostazol increase exercise time until intermittent 
claudication develops. Chelation therapy should be avoided. Indications for lower extremity 
percutaneous transluminal angioplasty or bypass surgery are (1) incapacitating claudication in 
patients interfering with work or lifestyle; (2) limb salvage in patients with limb-threatening 
ischemia as manifested by rest pain, nonhealing ulcers, and/or infection or gangrene; and 
(3) vasculogenic impotence.
Keywords: peripheral arterial disease, intermittent claudication, antiplatelet drugs, 
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revascularization
Introduction
Peripheral arterial disease (PAD) is chronic arterial occlusive disease of the lower 
extremities caused by atherosclerosis. PAD may cause intermittent claudication which 
is pain or weakness with walking that is relieved with rest. The muscle pain or weakness 
after exercise occurs distal to the arterial obstruction. Since the superﬁ  cial femoral and 
popliteal arteries are most commonly affected by atherosclerosis, the pain of intermit-
tent claudication is most commonly localized to the calf. Atherosclerotic obstruction 
of the distal aorta and its bifurcation into the two iliac arteries may cause pain in the 
buttocks, hips, thighs, or the inferior back muscles as well as the calves.
The Rutherford classiﬁ  cation of PAD includes 7 stages (Dormandy et al 2000). 
PAD is classiﬁ  ed as stage 0 if the person is asymptomatic, stage 1 if mild intermittent 
claudication is present, stage 2 if moderate intermittent claudication is present, stage 3 
if severe intermittent claudication is present, stage 4 if ischemic rest pain is present, 
stage 5 if the person has minor tissue loss, and stage 6 if the person has ulceration or 
gangrene.
Only one-half of elderly persons with documented PAD are symptomatic. Persons 
with PAD may not walk far or fast enough to induce muscle ischemic symptoms 
because of comorbidities such as pulmonary disease or arthritis, may have atypi-
cal symptoms unrecognized as intermittent claudication, may fail to mention their 
symptoms to their physician, or may have sufﬁ  cient collateral arterial channels to 
tolerate their arterial obstruction. Women with PAD have a higher prevalence of leg 
pain on exertion and at rest, poorer functioning, and greater walking impairment from 
leg symptoms than men with PAD (McDermott et al 2003a). Poorer leg strength in 
women contributes to poorer lower extremity functioning in women with PAD than Clinical Interventions in Aging 2007:2(4) 646
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in men with PAD. Upper extremity PAD will cause unequal 
blood pressure measurements in each arm. PAD patients 
also have a higher prevalence of cognitive impairment and 
erectile dysfunction.
If the arterial ﬂ  ow to the lower extremities cannot meet the 
needs of resting tissue metabolism, critical lower extremity 
ischemia occurs with pain at rest or tissue loss. Critical isch-
emia causes rest pain in the toes or foot with progression to 
ulceration or gangrene. Chronic arterial insufﬁ  ciency ulcers 
commonly develop at the ankle, heel, or leg. Mummiﬁ  ed, 
dry, black toes or devitalized soft tissue covered by a crust 
is gangrene caused by ischemic infarction. Suppuration 
often develops with time, and dry gangrene changes to wet 
gangrene.
Physical examination
The vascular physical examination includes (1) measurement 
of the blood pressure in both arms, (2) palpation of the carotid 
pulses and listening for carotid bruits, (3) auscultation of the 
abdomen and ﬂ  ank for bruits, (4) palpation of the abdomen 
and notation of the presence of the aortic pulsation and its 
maximal diameter, (5) palpation of pulses at the brachial, 
radial, ulnar, femoral, popliteal, dorsalis pedis, and posterior 
tibial sites, and (6) auscultation of both femoral arteries for 
femoral bruits (Hirsch et al 2006).
The shoes and socks should be removed and the feet 
inspected. The color, temperature, and integrity of the skin 
should be evaluated and the presence of distal hair loss, tro-
phic skin changes, hypertrophic nails, and ulcerations noted 
(Hirsch et al 2006).
Noninvasive diagnosis
Persons with PAD of the lower extremities have reduced or 
absent arterial pulses. Noninvasive tests used to assess lower 
extremity arterial blood ﬂ  ow include measurement of ankle 
and brachial artery systolic blood pressures, characteriza-
tion of velocity wave form, and duplex ultrasonography. 
Measurement of ankle and brachial artery systolic blood 
pressures using a Doppler stethoscope and blood pressure 
cuffs allows calculation of the ankle-brachial index (ABI) 
which is normally 0.9–1.2. An ABI of 0.90 is 95% sensitive 
and 99% speciﬁ  c for the diagnosis of PAD (McDermott et al 
2002). The lower the ABI, the more severe the restriction of 
arterial blood ﬂ  ow, and the more serious the ischemia. ABIs 
of 0.6–0.9 usually correlate with mild to moderate intermit-
tent claudication. ABIs of 0.4−0.6 usually correlate with 
severe intermittent claudication. With ABIs between 0.25 
and 0.4, rest pain and tissue loss are often found. Patients 
with calciﬁ  ed arteries from diabetes mellitus or renal failure 
occasionally have relatively non-compressible arteries lead-
ing to falsely elevated ABI values in the normal range.
In addition to measuring arterial pressure in non-palpable 
arteries, Doppler ultrasound methods allow characterization 
of the ﬂ  ow versus time velocity waveform. Finding biphasic 
ﬂ  ow at the groin or monophasic ﬂ  ow more distally is evidence 
of arterial obstruction even when ABI measurements are 
falsely increased to normal levels because of calciﬁ  cation.
Duplex ultrasonography combines Doppler frequency 
measurements with two-dimensional images of blood ves-
sels. The severity of ﬂ  ow restriction caused by an arterial 
stenosis can be accurately assessed by this most compre-
hensive noninvasive method (Kohler et al 1987). Dupex 
ultrasonography, computed tomographic angiography, and 
magnetic resonance angiography are useful in assessing the 
anatomic location and severity of PAD and in selecting suit-
able candidates for endovascular or surgical revascularization 
(Hirsch et al 2006).
Treadmill exercise testing with and without pre-exercise 
and postexercise ABIs helps differentiate claudication from 
pseudoclaudication in patients with exertional leg symptoms 
(Hirsch et al 2006). Treadmill exercise testing may be useful 
to diagnose PAD with a normal resting ABI but a reduced 
postexercise ABI. Treadmill exercise testing may objectively 
document the magnitude of symptom limitation in patients 
with claudication.
Prevalence
The prevalence of PAD increases with age (Criqui et al 1985; 
Newman et al 1993; Meijer et al 1998; Ness et al 2000; 
Hirsch et al 2001; Aronow et al 2002c; Ness et al 2005;). 
The prevalence of symptomatic PAD was 32% in 1160 men, 
mean age 80 years, and 26% in 2464 women, mean age 
81 year, living in a nursing home (Aronow et al 2002c). The 
prevalence of PAD in 6979 men and women, mean age 69 
years, screened for PAD by an ABI because they were aged 
70 years or older or because they were aged 50–69 years 
with a history of cigarette smoking or diabetes mellitus was 
29% (Hirsch et al 2001). Among these patients with PAD, 
classic claudication was present in only 11%.
Risk factors
Modiﬁ  able risk factors that predispose to PAD include 
cigarette smoking (Pomrehn et al 1986; Stokes et al 1987; 
Aronow et al 1988; Ness et al 2000; Sukhija et al 2003; 
Ness et al 2005), diabetes mellitus (Pomrehn et al 1986; 
Stokes et al 1987; Aronow et al 1988; Ness et al 2000; Clinical Interventions in Aging 2007:2(4) 647
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Sukhija et al 2003; Ness et al 2005), hypertension (Ness 
et al 2000; Ness et al 2005; Stokes et al 1987; Aronow et al 
1988; Sukhija et al 2003), dyslipidemia (Pomrehn et al 1986; 
Stokes et al 1987; Aronow et al 1994a; Ness et al 2000; 
Sukhija et al 2003; Ness et al 2005), increased plasma homo-
cysteine levels (Malinow et al 1989; Aronow et al 1998), and 
hypothyroidism (Mya et al 2003). Signiﬁ  cant independent 
risk factors for PAD in 467 men, mean age 80 years, and in 
1444 women, mean age 81 years, living in the community 
and seen in an academic geriatrics paractice were age (odds 
ratio = 1.05 for each 1-year increase in age in men and 1.03 
for each 1-year increase in age in women); current cigarette 
smoking (odds ratio = 2.6 for men and 4.6 for women); 
systolic or diastolic hypertension (odds ratio = 2.2 for men 
and 2.8 for women); diabetes mellitus (odds ratio = 6.1 for 
men and 3.6 for women); serum high-density lipoprotein 
cholesterol (odds ratio = 0.95 for each 1 mg/dL increase in 
men and 0.97 for each 1 mg/dL increase in women); and 
serum low-density lipoprotein (LDL) cholesterol (odds 
ratio = 1.02 for each 1 mg/dL increase in men and in women) 
(Ness et al 2000).
In 147 men and women with PAD and 373 men and women 
without PAD, mean age 81 years, plasma homocysteine was 
a signiﬁ  cant independent risk factor for PAD with an odds 
ratio of 1.13 for each 1 μmol/L increase (Aronow et al 1998). 
In 249 men and women, mean age 79 years, the prevalence 
of PAD was signiﬁ  cantly higher in persons with subclinical 
hypothyroidism (14 of 18 persons or 78%) than in persons with 
euthyroidism (40 of 231 persons or 17%) (Mya et al 2003).
Coexistence of other atherosclerotic 
disorders
PAD coexists with other atherosclerotic disorders (Aronow 
et al 1994b; Ness et al 1999; Sukhija et al 2003; Ness et al 
2005; Sukhija et al 2005). In a study of 1886 men and women, 
mean age 81 years, 270 of 468 persons (58%) with PAD had 
coexistent coronary artery disease (CAD) and 159 of 468 
persons (34%) with PAD had prior ischemic stroke (Aronow 
et al 1994b). In a study of 1,802 men and women, mean age 
80 years, living in the community and seen in an academic 
geriatrics practice, 161 of 236 persons (68%) with PAD had 
coexistent CAD and 100 of 236 persons (42%) with PAD had 
coexistent prior ischemic stroke (Ness et al 1999).
In 1,006 men and women, mean age 72 years, if PAD 
was present, 63% had coexistent CAD, and 43% had prior 
ischemic stroke (Ness et al 2005). In 273 patients, mean age 
71 years, with CAD, the lower the ABI, the higher the preva-
lence of 3-vessel or 4-vessel CAD (Sukhija et al 2005)
Cardiovascular mortality
and morbidity
Persons with PAD are at increased risk for all-cause mortality, 
cardiovascular mortality, and cardiovascular events (Smith 
et al 1990; Criqui et al 1992; Aronow et al 1992; Vogt et al 
1993; Newman et al 1997; Saw et al 2006). At 10-year 
follow-up of 565 men and women, mean age 66 years, PAD 
signiﬁ  cantly increased the risk of all-cause mortality (relative 
risk = 3.1), of mortality from cardiovascular disease (relative 
risk = 5.9), and of mortality from CAD (relative risk = 6.6) 
(Criqui et al 1992). At 4-year follow-up of 1492 women, 
mean age 71 years, an ABI of 0.9 or less was associated with 
a relative risk of 3.1 for all-cause mortality after adjustment 
for age, smoking, and other risk factors (Vogt et al 1993).
In a prospective study of 291 men and women, mean age 
82 years, with PAD, CAD was present in 160 persons (55%) 
(Aronow et al 1992). Silent myocardial ischemia detected by 
24-hour ambulatory electrocardiography was present in 60 
of 160 persons (38%) with PAD and CAD and in 26 of 131 
persons (20%) with PAD and no clinically evident CAD. At 
43-month follow-up, new coronary events developed in 54 
of 60 persons (90%) with PAD, CAD, and silent myocardial 
ischemia and in 59 of 100 persons (59%) with PAD, CAD, 
and no silent myocardial ischemia (Aronow et al 1992). New 
coronary events also developed in 18 of 26 persons (69%) 
with PAD, no CAD, and silent myocardial ischemia and in 
34 of 105 persons (32%) with PAD, no CAD, and no silent 
myocardial ischemia (Aronow et al 1992).
A pooled analysis of mortality in 8 large randomized 
percutaneous coronary intervention (PCI) trials of 19, 867 
patients showed that the presence of PAD was associated 
with higher rates of post-PCI death and myocardial infarction 
(MI) (Saw et al 2006). PAD was an independent predictor of 
short-term and of long-term mortality.
Risk factor modiﬁ  cation
Continuing smoking increases the risk of amputation in 
patients with intermittent claudication. Patency in lower 
extremity bypass grafts is also worse in smokers than in 
nonsmokers (Myers et al 1978). Smoking cessation reduces 
the progression of PAD to critical leg ischemia and reduces 
the risk of MI and death from vascular causes (Quick et al 
1982). Smoking cessation programs should be strongly 
encouraged in persons with PAD (Table 1).
Approaches to smoking cessation include use of nico-
tine patches or nicotine polacrilex gum, which are available 
over the counter. If this therapy is unsuccessful, nicotine 
nasal spray or treatment with the antidepressant buproprion Clinical Interventions in Aging 2007:2(4) 648
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should be considered A nicotine inhaler may also be used. 
The dosage and duration of treatment of each of these phar-
macotherapies are discussed in detail elsewhere (Frishman 
et al 2001). Concomitant behavioral therapy may also be 
needed. Repeated physician advice is very important in the 
treatment of smoking addiction.
Hypertension should be adequately controlled to decrease 
cardiovascular mortality and morbidity in persons with PAD 
(Chobanian et al 2003; Mehler et al 2003) (Table 1). The 
blood pressure should be reduced to 140/90 mm Hg and 
to 130/80 mm Hg in patients with diabetes mellitus or 
chronic renal insufﬁ  ciency. In the Heart Outcomes Prevention 
Evaluation (HOPE) Study, 1715 persons had symptomatic 
PAD, and 2118 persons had asymptomatic PAD with an ABI 
0.9 (Ostergren et al 2004). In the HOPE Study, compared 
with placebo, ramipril 10 mg daily signiﬁ  cantly reduced 
cardiovascular events by 25% in persons with symptomatic 
PAD. In this study, ramipril reduced the absolute incidence 
of cardiovascular events by 5.9% in persons with asymp-
tomatic PAD and by 2.3% in persons with a normal ABI. In 
the HOPE Study, the antihypertensive properties of ramipril 
did not completely account for the observed risk reduction 
(Ostergren et al 2004).
Among persons with PAD in the Appropriate Blood Pres-
sure Control in Diabetes trial, the incidence of cardiovascular 
events in persons treated with antihypertensive drug therapy 
with enalapril or nisoldipine was 13.6% if the mean blood 
pressure was reduced to 128/75 mm Hg versus 38.7% if the 
mean blood pressure was reduced to 137/81 mm Hg (Mehler 
et al 2003).
Elderly persons with diabetes mellitus and PAD and no 
CAD have a 1.5 times higher incidence of new coronary 
events than elderly nondiabetics with PAD and prior MI 
(Aronow et al 2003a). The higher the hemoglobin A1c levels 
in patients with diabetes mellitus and PAD, the higher the 
prevalence of severe PAD (Aronow et al 2007). Diabetes mel-
litus should be treated with the hemoglobin A1c level decreased 
to less than 7% to decrease the incidence of MI (Stratton et al 
2000) (Table 1). The blood pressure should be reduced to less 
than 130/80 mm Hg in elderly persons with PAD and diabetes 
mellitus (Adler et al 2000; Chobanian et al 2003; Mehler et al 
2003) (Table 1). Elderly diabetics with PAD should also be 
treated with statins (Aronow et al 2002a; Aronow 2002b; 
Grundy et al 2004) and the serum LDL cholesterol reduced 
to 70 mg/dL (Grundy et al 2004) (Table 1).
Treatment of dyslipidemia with statins has been docu-
mented to reduce the incidence of mortality, cardiovascular 
events, and stroke in persons with PAD with and without 
CAD (Pedersen et al 1998; HPS 2002; Aronow et al 2002a). 
At 5-year follow-up of 4444 men and women with CAD and 
hypercholesterolemia in the Scandinavian Simvastatin Sur-
vival Study, compared with placebo, simvastatin signiﬁ  cantly 
decreased the incidence of intermittent claudication by 38% 
(Pedersen et al 1998).
In a study of 264 men and 396 women, mean age 80 years, 
with symptomatic PAD and a serum LDL cholesterol of 
125 mg/dL or higher, 318 of 660 persons (48%) were treated 
with a statin and 342 of 660 persons (52%) with no lipid-
lowering drug (Aronow et al 2002a). At 39-month follow-
up, treatment with statins caused a signiﬁ  cant independent 
reduction in the incidence of new coronary events of 58%, 
of 52% in persons with prior MI, and of 59% in persons with 
no prior MI (Aronow et al 2002a).
In the Heart Protection Study (HPS), 6748 of the 20536 
persons (33%) had PAD (HPS 2002). At 5-year follow-up, 
treatment with simvastatin 40 mg daily caused a signiﬁ  cant 
19% relative reduction and a 6.3% absolute reduction in 
major cardiovascular events independent of age, gender, or 
serum lipids levels (HPS 2002). These data favor adminis-
tration of statins to elderly persons with PAD regardless of 
serum lipids levels.
On the basis of the available data, elderly persons with 
PAD and hypercholesterolemia should be treated with 
statins to reduce cardiovascular mortality and morbidity 
and progression of PAD (Pedersen et al 1998; Aronow et al 
2002a; HPS 2002) and to improve exercise time until inter-
mittent claudication (Aronow et al 2003b; Mohler et al 2003; 
Mondillo et al 2003). On the basis of data from the HPS, 
persons with PAD should be treated with statins regardless 
of age, gender, or initial serum lipids levels (HPS 2002).
Table 1 Medical management of peripheral arterial disease in 
the elderly
  1.  Smoking cessation program
  2.  Treatment of hypertension with blood pressure reduced to
  140/90 mm Hg and to 130/80 mm Hg in patients with diabetes
  mellitus or chronic renal insufﬁ  ciency
  3.  Control diabetes mellitus with the hemoglobin A1c level reduced
 to  7%
  4.  Treat dyslipidemia and reduce serum low-density lipoprotein
 cholesterol  to  70 mg/dL
  5.  Antiplatelet drug therapy with aspirin or preferably clopidogrel
  6.  Treatment with an angiotensin-converting enzyme inhibitor
  7.  Treatment with beta blockers in patients with coronary artery
  disease in the absence of contraindications to these drugs
  8.  Use of statins
  9.  Treatment with cilostazol in patients with intermittent claudication
10.  Exercise rehabilitation program
11. Foot  careClinical Interventions in Aging 2007:2(4) 649
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Increased plasma homocysteine level is a risk factor for 
PAD (Malinow et al 1989; Aronow et al 1998). Reduction 
of increased plasma homocysteine levels can be achieved 
by administering a combination of folic acid, vitamin B6, 
and vitamin B12. However, we do not have double-blind, 
randomized, placebo-controlled data showing that reduc-
tion of increased plasma homocysteine levels will reduce 
coronary events and slow progression of PAD in elderly 
persons with PAD.
Hypothyroidism is a risk factor for PAD (Mya et al 2003). 
Elderly persons with clinical or subclinical hypothyroidism 
should be treated with l-thyroxine to decrease the develop-
ment of CAD (Mya et al 2002). There is no evidence showing 
that treatment with l-thyroxine will reduce the development 
of PAD or improve symptoms.
Antiplatelet drugs
Antiplatelet drugs that have been shown to decrease the 
incidence of vascular death, nonfatal MI, and nonfatal 
stroke in persons with PAD are aspirin, ticlodipine, and 
clopidogrel (ATCG 2002). Aspirin plus dipyridamole has 
not been shown to be more efﬁ  cacious than aspirin alone in 
the treatment of persons with PAD (ATCG 2002). Adverse 
hematologic effects associated with ticlodipine limit the use 
of this drug in the treatment of elderly persons with PAD 
(Bennett et al 1998).
The Antithrombotic Trialists’ Collaboration Group(ATCG) 
reported a meta-analysis of 26 randomized studies of 6,263 
persons with intermittent claudication due to PAD (ATCG 
2002). At follow-up, the incidence of vascular death, nonfatal 
MI, and nonfatal stroke was 6.4% in patients randomized 
to antiplatelet drugs versus 7.9% in the control group, a 
signiﬁ  cant reduction of 23% caused by antiplatelet therapy.
The reductions are signiﬁ  cant for all subgroups.
The ATCG reported a meta-analysis of 12 randomized 
studies of 2,497 persons with PAD undergoing peripheral 
arterial grafting (ATCG 2002). At follow-up, the incidence 
of vascular death, nonfatal MI, and nonfatal stroke was 5.4% 
in persons randomized to antiplatelet drugs versus 6.5% in 
the control group, a signiﬁ  cant reduction of 22% caused by 
antiplatelet therapy.
The ATCG also reported a meta-analysis of 4 random-
ized studies of 946 persons with PAD undergoing peripheral 
angioplasty (ATCG 2002) At follow-up, the incidence of 
vascular death, nonfatal MI, and nonfatal stroke was 2.5% 
in patients randomized to antiplatelet drugs versus 3.6% in 
the control group, a signiﬁ  cant reduction of 29% caused by 
antiplatelet therapy.
If one combines the 42 randomized studies of 9,706 
patients with intermittent claudication, peripheral arterial 
grafting, or peripheral angioplasty, the incidence of vascular 
death, nonfatal MI, and nonfatal stroke at follow-up was sig-
niﬁ  cantly decreased 23% by antiplatelet drugs, with similar 
beneﬁ  ts among patients with intermittent claudication, those 
having peripheral arterial grafting, and those having periph-
eral angioplasty (ATCG 2002). These data favor the use of 
aspirin in men and women with PAD (Table 1).
Aspirin
The ATCG showed that the efﬁ  cacy of different doses of 
aspirin in reducing in high-risk persons the incidence of 
vascular death, nonfatal MI, and nonfatal stroke was 19% 
for aspirin 500–1500 mg daily, 26% for aspirin 160–325 mg 
daily, 32% for aspirin 75–150 mg daily, and 13% for aspirin 
75 mg daily (ATCG 2002). Since aspirin doses greater 
than 150 mg daily do not reduce vascular death, nonfatal 
MI, and nonfatal stroke more than does a dose of 75 to 150 
mg daily and cause more gastrointestinal bleeding than 
the lower doses, this author prefers an aspirin dose of 81 
mg daily in treating elderly persons with atherosclerotic 
vascular disease.
Clopidogrel
In the Clopidogrel versus Aspirin in Patients at Risk for 
Ischaemic Events (CAPRIE) trial, 5,795 persons with PAD 
were randomized to clopidogrel 75 mg daily and 5797 per-
sons with PAD were randomized to aspirin 325 mg daily 
(CAPRIE 1996). At 1.9-year follow-up, the annual inci-
dence of vascular death, nonfatal MI, and nonfatal stroke 
was 3.7% in persons randomized to clopidogrel versus 
4.9% in persons randomized to aspirin, a 24% signiﬁ  cant 
decrease with the use of clopidogrel (CAPRIE 1996). In 
9478 patients with prior MI, ischemic stroke, or symptom-
atic PAD in the Clopidogrel for High Atherothrombotic 
Risk and Ischemic Stabilization, Management, and Avoid-
ance (CHARISMA) trial, addition of clopidogrel to aspirin 
signiﬁ  cantly reduced cardiovascular death, MI, or stroke 
by 17% (Bhatt et al 2007).
On the basis of these data, it is reasonable to conclude 
that clopidogrel is superior to aspirin in the management of 
patients with PAD. On the basis of these data, the author 
also recommends the use of clopidogrel 75 mg daily in 
the treatment of patients with PAD (Table 1). However, 
clopidogrel is much more expensive than is aspirin. Clopido-
grel but not aspirin is approved by the USA Food and Drug 
Administration for the treatment of PAD.Clinical Interventions in Aging 2007:2(4) 650
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Oral anticoagulants
In the Dutch Bypass Oral Anticoagulants or Aspirin Study, 
2690 persons were randomized after infrainguinal bypass 
surgery to aspirin 80 mg daily or to oral anticoagulation 
with phenprocoumon or acenocoumarol to maintain an INR 
of 3.0–4.5 (BOA Study group 2000). At 21-month follow-
up, there was no signiﬁ  cant difference between the two 
treatments in the primary outcome of infrainguinal graft 
occlusion. There was no signiﬁ  cant difference between the 
two treatments in the secondary outcomes of MI, stroke, 
amputation, or vascular death. However, persons treated 
with oral anticoagulant therapy had 1.96 times more major 
bleeding episodes than persons treated with oral aspirin. The 
American College of Cardiology (ACC)/American Heart 
Association (AHA) guidelines state that oral anticoagulant 
therapy with warfarin should not be given to reduce the risk 
of adverse cardiovascular ischemic events in persons with 
atherosclerotic lower extremity PAD (Hirsch et al 2006).
Angiotensin-converting enzyme 
inhibitors
Data from the HOPE Study showed that ramipril 10 mg daily 
signiﬁ  cantly decreased cardiovascular events in persons with 
symptomatic PAD and in persons with asymptomatic PAD 
(Ostergren et al 2004). Angiotensin-converting enzyme 
inhibitors as well as statins also have many pleotropic effects 
to account for their vascular protective properties beyond 
their primary mode of action including inhibition of cellular 
proliferation, restoration of endothelial activity, inhibition 
of platelet reactivity, and an antioxidant potential (Faggioto 
et al 1999). The ACC/AHA guidelines recommend treating 
persons with PAD with angiotensin-converting enzyme 
inhibitors unless there are contraindications to the use of 
these drugs to reduce cardiovascular mortality and morbidity 
(Smith et al 2001) (Table 1).
Beta blockers
Persons with PAD are at increased risk for developing 
new coronary events (Smith et al 1990; Criqui et al 1992; 
Aronow et al 1992; Vogt et al 1993; Newman et al 1997; 
Saw et al 2006). Many physicians have been reluctant to 
use beta blockers in persons with PAD because of concerns 
that beta blockers will aggravate intermittent claudication. 
However, a meta-analysis of 11 randomized controlled 
studies found that beta blockers do not adversely effect 
walking capacity or the symptoms of intermittent clau-
dication in persons with mild-to-moderate PAD (Radack 
et al 1991).
An observational study was performed in 575 men and 
women, mean age 80 years, with symptomatic PAD and 
prior MI (Aronow et al 2001). Of the 575 persons, 85 persons 
(15%) had contraindications to the use of beta blockers. Of 
the 490 persons without contraindications to the use of beta 
blockers, 257 persons (52%) were treated with beta blockers. 
Adverse effects causing cessation of beta blockers occurred in 
31 of the 257 persons (12%). At 32-month follow-up, use of 
beta blockers caused a 53% signiﬁ  cant independent decrease 
in the incidence of new coronary events in elderly persons 
with PAD and prior MI (Aronow et al 2001). Beta blockers 
should be used to treat CAD in patients with PAD in the 
absence of contraindications to these drugs (Table 1).
Statins
On the basis of data from the HPS, persons with PAD should 
be treated with statins regardless of age, gender, or initial 
serum lipids levels (HPS 2002) (Table 1). In 6748 persons 
with PAD in the HPS study, simvastatin caused an abso-
lute reduction in ﬁ  rst major vascular event of 63 per 1000 
patients treated (HPS 2007). Three double-blind, randomized, 
placebo-controlled studies have also demonstrated that statins 
improve walking performance in persons with PAD (Aronow 
et al 2003b; Mohler et al 2003; Mondillo et al 2003).
In a study of 69 persons, mean age 75 years, with inter-
mittent claudication, a mean ABI of 0.63, and a serum LDL 
cholesterol of 125 mg/dL or higher, 3 of 34 persons (9%) 
treated with simvastatin and 6 of 35 persons (17%) treated 
with placebo died before the 1-year study was completed 
(Aronow et al 2003b). Compared with placebo, simvastatin 
signiﬁ  cantly increased the treadmill exercise time until the 
onset of intermittent claudication by 24% at 6 months and 
by 42% at 1 year after therapy.
In a study of 354 persons, mean age 68 years, with 
intermittent claudication and hypercholesterolemia, at 
1-year follow-up, compared with placebo, atorvastatin 80 mg 
daily signiﬁ  cantly improved pain-free treadmill walking 
distance by 40% and signiﬁ  cantly improved community-
based physical activity (Mohler et al 2003). In a study of 
86 persons, mean age 67 years, with intermittent claudication 
and hypercholesterolemia, at 6-month follow-up, compared 
with placebo, simvastatin 40 mg daily signiﬁ  cantly improved 
pain-free walking distance and total walking distance on a 
treadmill, signiﬁ  cantly improved the mean ABI at rest and 
after exercise, and signiﬁ  cantly improved symptoms of 
claudication (Mondillo et al 2003).
Statin use is also associated with superior leg function-
ing independent of cholesterol levels and other potential Clinical Interventions in Aging 2007:2(4) 651
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confounders (McDermott et al 2003b). The data suggest that 
non-cholesterol-lowering properties of statins may favorably 
inﬂ  uence functioning in persons with and without PAD 
(McDermott et al 2003b).
Drugs to increase walking distance
Chelation therapy has been demonstrated to be ineffective in 
the therapy of PAD (Ernst 1997). Numerous drugs have been 
shown to be ineffective in improving walking distance in 
persons with intermittent claudication (Hiatt 2001; Eberhardt 
et al 2000). Beraprost sodium, an orally active prostaglandin 
I2 analogue, was demonstrated to be no more effective than 
placebo in persons with intermittent claudication (Mohler 
et al 2003). Naftidrofuryl (Lehert et al 1994) and propionyl 
levocarnitine (Brevetti et al 1999) have been reported to 
improve exercise walking distance in persons with intermit-
tent claudication but have not been approved for use in the 
United States.
Two drugs, pentoxifylline and cilostazol, have been 
approved by the United States Food and Drug Administration 
for symptomatic treatment of intermittent claudication. How-
ever, many studies have found no consistent improvement 
with pentoxifylline in patients with intermittent claudication 
in comparison with placebo (Porter et al 1982; Dawson et al 
2000; Eberhardt et al 2000).
Cilostazol inhibits phosphodiesterase type 3, increasing 
intracellular concentration of cyclic adenosine monophos-
phate. Cilostazol suppresses platelet aggregation and also acts 
as a direct arterial vasodilator. Cilostazol has been found in 
numerous trials to improve exercise capacity in patients with 
intermittent claudication (Dawson et al 1998; Money et al 
1998; Eberhardt et al 2000; Thompson et al 2002; Dawson 
et al 2000). and in a dose of 100 mg twice daily, was shown 
to be superior to both placebo and pentoxifylline (Dawson 
et al 2000).
Cilostazol should be administered to patients with PAD 
to increase walking distance (Table 1) but should not be 
given to persons with PAD who also have heart failure. Other 
contraindications to the use of cilostazol include a creatinine 
clearance 25 ml/min, a known predisposition for bleeding, 
or coadministration of CYP3A4 or CYP2C19 inhibitors such 
as cimetidine, diltiazem, erythromycin, ketoconazole, lanso-
prazole, omeprazole, and HIV-1 protease inhibitors.
Exercise rehabilitation
Exercise rehabilitation programs have been documented 
to increase walking distance in persons with intermittent 
claudication through improvements in peripheral circulation, 
walking economy, and cardiopulmonary function (Gardner 
et al 2000). The optimal exercise program for improving 
claudication pain distance in persons with PAD uses inter-
mittent walking to near-maximal pain during a program of 
at least 6 months (Gardner et al 1995). Strength training is 
less effective than treadmill walking (Hiatt et al 1994). The 
ACC/AHA guidelines recommend a supervised exercise 
program for patients with intermittent claudication (Hirsch 
et al 2006) (Table 1).
Supervised exercise training is recommended for a 
minimum of 30–45 minutes in sessions performed at least 
3 times per week for a minimum of 12 weeks (Hirsch et al 
2006) and preferably for 6 months or longer (Gardner et al 
1995). Among persons with PAD, self-directed walking 
exercise performed at least 3 times weekly is associated with 
signiﬁ  cantly less functional decline during the subsequent 
year (McDermott et al 2006).
Foot care
Persons with PAD must have proper foot care (Fujitani et al 
2004; Hirsch et al 2006) (Table 1). They must wear properly 
ﬁ  tted shoes. Careless nail clipping or injury from walking 
barefoot must be avoided. Feet should be washed daily and 
the skin kept moist with topical emollients to prevent cracks 
and ﬁ  ssures, which may have portals for bacterial infection. 
Fungal infection of the feet must be treated. Socks should 
be wool or other thick fabrics, and padding or shoe inserts 
may be used to prevent pressure sores.
Lower extremity angioplasty
and bypass surgery
Indications for lower extremity percutaneous transluminal 
angioplasty or bypass surgery are (1) incapacitating claudi-
cation in persons interfering with work or lifestyle; (2) limb 
salvage in persons with limb-threatening ischemia as mani-
fested by rest pain, nonhealing ulcers, and/or infection or 
gangrene; and (3) vasculogenic impotence (Weitz et al 1996). 
Percutaneous transluminal angioplasty can be performed if 
there is a skilled vascular interventionalist and the arterial 
disease is localized to a vessel segment less than 10 cm in 
length (Weitz et al 1996). Compared to percutaneous trans-
luminal angioplasty alone, stenting improves 3-year patency 
by 26%) (Palmaz et al 1990).
Percutaneous balloon angioplasty and/or stenting is 
indicated for short-segment stenoses, whereas multisegment 
disease and occlusions are most effectively treated with surgi-
cal revascularization (Comerota 2001). Revascularization of 
PAD is discussed extensively elsewhere (Hirsch et al 2006;Clinical Interventions in Aging 2007:2(4) 652
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Fujitani et al 2004). In patients presenting with severe limb 
ischemia caused by infra-inguinal disease and who are suitable 
for either surgery or angioplasty, by-pass surgery and balloon-
angioplasty are associated with similar outcomes in terms of 
amputation-free survival. (Basil 2005). Patients with intermit-
tent claudication should be considered for revascularization to 
improve symptoms only in the absence of other disease that 
would limit exercise improvement such as angina pectoris, 
heart failure, chronic pulmonary disease, or orthopedic limita-
tions (Hirsch et al 2006).
Amputation
Nonrandomized studies have demonstrated that both imme-
diate and long-term survival are higher in patients having 
revascularization rather than amputation for limb-threatening 
ischemia (Ouriel et al 1988; DeFrang et al 1991). However, 
amputation of lower extremities should be performed if tissue 
loss has progressed beyond the point of salvage, if surgery 
is too risky, if life expectancy is very low, or if functional 
limitations diminish the beneﬁ  t of limb salvage (Fujitani 
et al 2004).
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